Literature DB >> 22610922

Fidaxomicin failures in recurrent Clostridium difficile infection: a problem of timing.

Robert Orenstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22610922     DOI： 10.1093/cid/cis495

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  12 in total

Review 1.  Management of adult Clostridium difficile digestive contaminations: a literature review.

Authors:  Fanny Mathias; Christophe Curti; Marc Montana; Charléric Bornet; Patrice Vanelle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-29       Impact factor: 3.267

2.  Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.

Authors:  Marie Pichenot; Rozenn Héquette-Ruz; Remi Le Guern; Bruno Grandbastien; Clément Charlet; Frédéric Wallet; Sophie Schiettecatte; Fanny Loeuillet; Benoit Guery; Tatiana Galperine
Journal:  Infection       Date:  2017-01-24       Impact factor: 3.553

Review 3.  Clostridium difficile infection: management strategies for a difficult disease.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

4.  Prospects for flavonoid and related phytochemicals as nature-inspired treatments for Clostridium difficile infection.

Authors:  X Wu; M Z Alam; L Feng; L S Tsutsumi; D Sun; J G Hurdle
Journal:  J Appl Microbiol       Date:  2014-01       Impact factor: 3.772

5.  The membrane as a target for controlling hypervirulent Clostridium difficile infections.

Authors:  Xiaoqian Wu; Philip T Cherian; Richard E Lee; Julian G Hurdle
Journal:  J Antimicrob Chemother       Date:  2012-12-21       Impact factor: 5.790

6.  Small-Molecule Inhibition of the C. difficile FAS-II Enzyme, FabK, Results in Selective Activity.

Authors:  Jesse A Jones; Allan M Prior; Ravi K R Marreddy; Rebecca D Wahrmund; Julian G Hurdle; Dianqing Sun; Kirk E Hevener
Journal:  ACS Chem Biol       Date:  2019-06-26       Impact factor: 5.100

7.  Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies.

Authors:  Melinda M Soriano; Larry H Danziger; Dale N Gerding; Stuart Johnson
Journal:  Open Forum Infect Dis       Date:  2014-08-25       Impact factor: 3.835

8.  A multi-center study of fidaxomicin use for Clostridium difficile infection.

Authors:  Dhara N Shah; Fay S Chan; Nandita Kachru; Krutina P Garcia; Holly E Balcer; April P Dyer; John E Emanuel; Michelle D Jordan; Katherine T Lusardi; Geri Naymick; Radhika S Polisetty; Lanny Sieman; Ashley M Tyler; Michael L Johnson; Kevin W Garey
Journal:  Springerplus       Date:  2016-08-02

9.  Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France.

Authors:  Emilie Baro; Tatiana Galperine; Fanette Denies; Damien Lannoy; Xavier Lenne; Pascal Odou; Benoit Guery; Benoit Dervaux
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

10.  Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo.

Authors:  George A Naclerio; Nader S Abutaleb; Daoyi Li; Mohamed N Seleem; Herman O Sintim
Journal:  J Med Chem       Date:  2020-10-06       Impact factor: 8.039
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.